Welcome!

News Feed Item

Global Protein Therapeutics Market Outlook 2018

NEW YORK, Jan. 20, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Protein Therapeutics Market Outlook 2018
http://www.reportlinker.com/p01974624/Global-Protein-Therapeutics-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Protein based therapies have found a prominent place in the biopharmaceutical industry since the launch of the human insulin product. They have become one of the most effective clinical methods to treat a wide spectrum of diseases ranging from cancer to metabolic disorders. The market holds tremendous potential for future growth and it is estimated that by the end of 2018, it may reach the mark of US$ 165 Billion as new products (especially monoclonal antibodies in the advanced clinical phase) may enter the sector.

According to our new research report, "Global Protein Therapeutics Market Outlook 2018", a large number of market players has been developing monoclonal antibodies (mAbs). Our research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments.

Through in-depth and prudent analysis of the developments taking place at the global level, we have observed that the US holds a dominant position in the global protein therapeutics market as the country provides a major proportion of the products' sales. However, our team of researchers has come up with an analysis that the future landscape of the market may find positive developments from Asian countries as huge patients' population and increasing disposable incomes may turn out to be a win-win condition for industry participants.

The report also covers an advanced phase drug analysis. This chapter lists all the protein therapeutics of the major players which are in the third phase of the clinical trial. This analysis will help the client in understanding the potential market for the future. It also helps understand the major segments, indications and players in Protein Therapeutics that will continue to rule the market.

The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance.

At the end, the key players of the market have been enlisted. A brief business overview of every player has been provided alongwith its product portfolio. This is followed by the recent developments of the player that may impact the market in the future. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
1. Analyst View
2. Research Methodology
3. Global Protein Therapeutics Market
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2018
3.2.1 Market Segmentation
4. Industry Performance
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2018
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2018
4.2.3 By Application
4.2.4 Key Geographical Markets

4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3 Insulin
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2018
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2018
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2018
4.5.3 Key Geographical Markets
4.5.4 Key Players and Drugs
4.5.5 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2018
4.6.3 Key Players and Drugs
4.6.4 Recent Developments

4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2018
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2018
4.8.3 Key Players and Drugs
4.8.4 Recent Developments
5. Advanced Phase Drugs Analysis
6. Emerging Market Trends
6.1 Gaining Momentum: Strategic Activities among Players to Develop Novel Treatments
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Players Investing Heavily in Multiple Sclerosis and Cancer Therapeutics
7. Key Players
7.1 Johnson & Johnson
7.2 Biogen Idec Inc.
7.3 Eli Lilly & Company
7.4 Sanofi-Aventis
7.5 Merck Serono S.A.
7.6 Roche Group
7.7 Amgen Inc.
7.8 Pfizer
7.9 Abbott Laboratories
7.10 Novo Nordisk

List of Figures:

Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2012
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2012-2018
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2012
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2018
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-2: Global - Monoclonal Antibodies Market by Application (%), 2012
Figure 4-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2011 & 2012
Figure 4-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2011 & 2012
Figure 4-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2011 & 2012
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-9: Global - Erythropoietin Market (Billion US$), 2012-2018
Figure 4-10: Global - Number of Patients on Dialysis (Million), 2010-2012
Figure 4-11: Global - Breakup of Patients on Dialysis by Region (%), 2012
Figure 4-12: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-13: Global - Breakup of New Cancer Cases by Region (%), 2009
Figure 4-14: Global - Share of US in EPO Market (2012)
Figure 4-15: Global - Insulin Market (Billion US$), 2012-2018

Figure 4-16: Global - Number of Diabetic Patients (Million), 2012 & 2030
Figure 4-17: China - Insulin Market (Billion US$), 2012-2018
Figure 4-18: US - Insulin Market (Billion US$), 2012-2018
Figure 4-19: Japan - Insulin Market (Billion US$), 2012-2018
Figure 4-20: Global - Share of Key Players in Insulin Market (2012)
Figure 4-21: Global - Share of Products in Insulin Market (2012)
Figure 4-22: Global - Interferon Market (Billion US$), 2012-2018
Figure 4-23: Global - Share of Alpha and Beta Products in Interferon Market (2012)
Figure 4-24: Global - Interferon Alpha Market (Billion US$), 2010-2012
Figure 4-25: Global - Interferon Beta Market (Billion US$), 2010-2012
Figure 4-26: US - Interferon Market (Billion US$), 2010-2012
Figure 4-27: Japan - Interferon Market (Million US$), 2010-2012
Figure 4-28: Global - Human Growth Hormone Market (Billion US$), 2012-2018
Figure 4-29: Global - Share of Key Players in Human Growth Hormone Market (2012)
Figure 4-30: Global - Blood Clotting Factor Market (Billion US$), 2012-2018
Figure 4-31: Global - Share of Blood Clotting Factor Market by Segment (2012)
Figure 4-32: Global - Share of Key Players in Blood Clotting Factor Market (2012)
Figure 4-33: Global - Follicle Stimulating Hormone Market (Billion US$), 2012-2018
Figure 4-34: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2018

List of Tables:

Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2010-2012
Table 4-2: US - Sales of Key EPO Products (Billion US$), 2010-2012
Table 4-3: Global - Key Players and Drugs in Erythropoietin Alfa Market (Billion US$), 2010-2012
Table 4-4: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2010-2012
Table 4-5: Global - Key Players and Drugs in Darbepoetin Market (Billion US$), 2010-2012
Table 4-6: China - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030f
Table 4-7: US - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030f
Table 4-8: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030
Table 4-9: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2010-2012
Table 4-10: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2010-2012
Table 4-11: Global - Key Players and Drugs in Human Growth Hormone Market (Billion US$), 2010-2012
Table 4-12: Global - Key Players and Drugs in Blood Clotting Factor Market (Billion US$), 2010-2012
Table 4-13: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Billion US$), 2010-2012
Table 4-14: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Billion US$), 2010-2012
Table 5-1: Advanced Phase Protein Therapeutics
Table 7-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 7-2: Biogen Idec - Key Products in Protein Therapeutics
Table 7-3: Eli Lilly - Key Products in Protein Therapeutics
Table 7-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 7-5: Merck Serono - Key Products in Protein Therapeutics
Table 7-6: Roche - Key Products in Protein Therapeutics
Table 7-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 7-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 7-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 7-10: Novo Nordisk - Key Products in Protein Therapeutics

To order this report: Global Protein Therapeutics Market Outlook 2018
http://www.reportlinker.com/p01974624/Global-Protein-Therapeutics-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
"Digital transformation - what we knew about it in the past has been redefined. Automation is going to play such a huge role in that because the culture, the technology, and the business operations are being shifted now," stated Brian Boeggeman, VP of Alliances & Partnerships at Ayehu, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"WineSOFT is a software company making proxy server software, which is widely used in the telecommunication industry or the content delivery networks or e-commerce," explained Jonathan Ahn, COO of WineSOFT, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
Sanjeev Sharma Joins June 5-7, 2018 @DevOpsSummit at @Cloud Expo New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
Digital Transformation (DX) is not a "one-size-fits all" strategy. Each organization needs to develop its own unique, long-term DX plan. It must do so by realizing that we now live in a data-driven age, and that technologies such as Cloud Computing, Big Data, the IoT, Cognitive Computing, and Blockchain are only tools. In her general session at 21st Cloud Expo, Rebecca Wanta explained how the strategy must focus on DX and include a commitment from top management to create great IT jobs, monitor ...